アフェレシス市場規模、シェア、動向、2031年までの世界予測

世界のアフェレシス市場は2026年の30億2000万米ドル規模となり、予測期間中に年平均成長率（CAGR）7.9%で成長し、2031年には44億1000万米ドルに達するとMarketsandMarketsでは予測しています。血液疾患、自己免疫疾患、神経疾患、腎疾患の罹患率の上昇、および世界的な血液成分や血漿製剤の需要増により、アフェレシス装置および技術の需要は着実に増加しています。病院、血液バンク、専門クリニックにおける治療用およびドナー用アフェレシス（血液浄化療法）技術の利用拡大が、市場の成長を支えています。医療施設は現在、採血効率を高め、患者の転帰を改善するために、高効率で完全自動化された、患者に優しいアフェレシス（アフェレーシス）システムの開発に注力しています。さらに、自動血液成分分離装置や連続フロー遠心分離機などの技術革新も市場の成長に貢献しています。加えて、発展途上国における採血施設の改善や医療機関の取り組みにより、効果的な血液管理が確保され、今後数年間、市場の力強い成長が維持されると予想されます。

MarketsandMarkets（マーケッツアンドマーケッツ）「アフェレシス市場 – 製品（医療機器、使い捨て製品）、手順［ドナー、治療（神経系、血液）］、用途（血漿分離、血小板分離）、技術（遠心分離、膜分離）、エンドユーザー（クリニック） – 2031年までの世界市場予測 – Apheresis Market by Product (Device, Disposable), Procedure [Donor, Therapeutic (Neurological, Blood)], Application (Plasmapheresis, Plateletpheresis), Technology (Centrifugation, Membrane Separation), End User (Clinic) – Global Forecast to 2031」はアフェレシスの世界市場を調査し、主要セグメント別に分析・予測を行っています。

調査概要

本レポートは、製品、タイプ、手順、技術、エンドユーザー、地域別にアフェレシス（血液浄化療法）市場を分析しています。また、市場成長に影響を与える要因、市場における機会と課題、そして市場リーダー間の競争環境についても詳細に解説しています。さらに、個々の成長傾向に基づいてマイクロマーケットを分析し、5つの主要地域（および各地域内の国々）における市場セグメントの収益予測を提供しています。

本レポートを購入する理由

本レポートは、既存企業だけでなく、新規参入企業や中小企業にとっても、市場の動向を把握し、より大きな市場シェアを獲得するのに役立ちます。本レポートを購入した企業は、以下の戦略のいずれか、または複数の戦略を組み合わせて、市場での存在感を強化することができます。

本レポートは、以下のポイントに関する洞察を提供します。

主要な推進要因（自己免疫疾患および神経疾患の罹患率の上昇、バイオ医薬品企業による血漿由来生物製剤の利用増加、血液成分の需要増加、輸血安全性への重視の高まり、複雑な腫瘍治療および移植手術の増加、成分特異的血液採取における技術革新、細胞・遺伝子治療の普及拡大）、阻害要因（アフェレシス技術の導入を制限する高額な処置および運用コスト、新興国におけるアフェレシス献血手順の普及の限定性、アフェレシス手順を制限する厳格な献血適格基準および献血者の不足、アフェレシス手順の導入に影響を与える熟練専門家の不足）、機会（白血病および小児患者におけるアフェレシス手順の導入によるアフェレシス（アフェレーシス）市場の成長機会、政府および主要業界プレーヤーによる新興国市場への投資の増加）、および課題（処置関連の有害事象のリスク、輸血感染症のリスク、不十分な血液スクリーニングインフラ）の分析。新興国を含む市場がアフェレーシス市場の成長に与える影響

• 市場浸透：アフェレシス（血液浄化療法）市場における主要企業の製品ポートフォリオに関する包括的な情報
• 製品開発／イノベーション：アフェレシス（血液浄化療法）市場における今後のトレンド、研究開発活動、製品開発に関する詳細な分析
• 市場開発：有望な新興地域に関する包括的な情報
• 市場多様化：アフェレシス（アフェレーシス）市場における新製品、成長地域、最新動向に関する包括的な情報
• 競合分析：主要企業の市場セグメント、成長戦略、収益分析、製品に関する詳細な分析

Report Description

The global apheresis market is projected to reach USD 4.41 billion by 2031 from USD 3.02 billion in 2026, growing at a CAGR of 7.9% during the forecast period.

The demand for apheresis equipment and techniques is growing steadily, driven by the rising incidence of hematological, autoimmune, neurological, and renal diseases, as well as the high demand for blood components and plasma-based products worldwide. Increasing use of therapeutic and donor apheresis techniques in hospitals, blood banks, and specialized clinics is supporting the growth of the market. Healthcare facilities are now focusing on developing highly efficient, fully automated, and patient-friendly apheresis systems to increase collection efficacy and improve patient outcomes. Additionally, technological innovations, including automated blood component separators and continuous flow centrifuges, are contributing to market growth. Moreover, improved blood collection facilities in developing countries and healthcare organizations’ initiatives ensure effective blood management and are expected to sustain strong market growth in the coming years.

“By product, the disposables are projected to capture a significant market share.”

By product, the disposables category holds the largest share of the global apheresis market, driven by rising numbers of blood collections and therapeutic apheresis procedures worldwide. Disposable kits, tubing assemblies, needles, and collection chambers are vital components of apheresis systems, as they ensure sterility, minimize the risk of contamination, and safeguard patients and donors. The repeated consumption of disposables and their replacement at each new apheresis procedure play a significant role in generating consistent revenue and ensuring product demand. The growing number of plasma collection, plateletpheresis, leukapheresis, and therapeutic plasma exchange procedures is another important factor driving growth in the disposables category. In addition, the increasing demand for plasma-based therapeutics, the rise in blood donations, and the growing acceptance of automated apheresis technology are contributing to the growing use of disposables.

“By procedure, the plasmapheresis segment is expected to register the highest share in 2025.”

By procedure, the plasmapheresis segment holds the largest market share in the apheresis market, driven by growing worldwide demand for plasma-derived therapies used to treat immunological, neurological, and hematological conditions. The plasmapheresis method is widely applied for obtaining donor plasma as well as conducting plasma exchange therapy, since it is highly efficient in plasma separation and collection while other components of the blood are returned to the body. Growth in the incidence of autoimmune diseases, higher demand for immunoglobulins and coagulation factors, and an increasing number of plasma donations worldwide are additional factors supporting the segment’s growth. Additionally, the widespread use of plasmapheresis procedures in blood centers and hospitals is facilitated by recent developments in automated plasmapheresis technology, which increase process efficiency and improve donor safety and productivity.

In 2025, North America accounted for the largest market share of the apheresis market by region.

The apheresis market is segmented into North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa. North America leads the global apheresis market; this dominance is attributed to the high incidence of hematological, autoimmune, neurological, and renal disorders, as well as robust demand for plasma-based products and blood components. The region benefits from an extensive healthcare and blood donation network, widespread use of apheresis techniques, and the involvement of major market players and plasma collection companies. In addition, increased awareness of blood donation, rising cases of apheresis treatment, favorable reimbursement policies, and investment in transfusion medicine and plasma collection facilities contribute to the market’s dominance in the region.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1–40%, Tier 2–35%, and Tier 3– 25%
• By Designation: Directors–23%, Managers–30%, and Others–47%
• By Region: North America–25%, Europe–35%, the Asia Pacific–20%, Latin America- 13%, and the Middle East & Africa- 7%

The prominent players in the apheresis market include Terumo Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Fresenius Medical Care AG (Germany), Asahi Kasei Medical Co., Ltd. (Japan), Becton, Dickinson and Company (US), Macopharma SA (France), Miltenyi Biotec (Germany), Therakos LLC (US), Toray Industries Inc. (Japan), Kaneka Corporation (Japan), and B. Braun SE (Germany).

Research Coverage

This report examines the apheresis market by product, type, procedure, technology, end user, and region. It also covers the factors affecting market growth, analyzes the opportunities and challenges in the market, and provides details on the competitive landscape among market leaders. Furthermore, the report analyzes micro-markets by their individual growth trends and forecasts revenue for market segments across five main regions (and the countries within these regions).

Reasons to Buy the Report

The report will enable established firms, as well as entrants/smaller firms, to gauge the market pulse, which, in turn, will help them gain a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence.

This report provides insights into the following pointers:

Analysis of key drivers (rising prevalence of autoimmune and neurological disorders, increasing utilization of plasma-derived biologics by biopharmaceutical companies, rising demand for blood components,  increasing emphasis on transfusion safety, growing volume of complex oncological and transplant procedures, technological improvements in component-specific blood collection, and expanding adoption of cell and gene therapies), restraints (high procedural and operational costs limiting adoption of apheresis technologies, limited adoption of apheresis donation procedures in emerging economies, stringent donor eligibility criteria and limited donor availability restraining apheresis procedures and dearth of skilled professionals impacting the adoption of apheresis procedures), opportunities (adoption of apheresis procedures in leukemia and pediatric patients creating growth opportunities for the apheresis market, and growing investments in emerging markets by governments and key industry players), and challenges (risk of procedure-related adverse events and risk of transfusion-transmitted infections and inadequate blood screening infrastructure in emerging countries) influencing the growth of apheresis market

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the apheresis market
• Product Development/Innovation: Detailed insights into the upcoming trends, R&D activities, and product developments in the apheresis market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the apheresis market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

Table of Contents

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.2.1 PRODUCT DEFINITION 31
1.2.2 TECHNOLOGY DEFINITION 31
1.2.3 PROCEDURE DEFINITION 31
1.2.4 END USER DEFINITION 32
1.2.5 INCLUSIONS & EXCLUSIONS 33
1.3 STUDY SCOPE 34
1.3.1 MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED 35
1.3.3 CURRENCY CONSIDERED 35
1.4 STAKEHOLDERS 35
1.5 SUMMARY OF CHANGES 36
2 EXECUTIVE SUMMARY 37
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 37
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 39
2.3 DISRUPTIVE TRENDS IN APHERESIS MARKET 40
2.4 HIGH-GROWTH SEGMENTS 40
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 41
3 PREMIUM INSIGHTS 42
3.1 APHERESIS MARKET OVERVIEW 42
3.2 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY AND END USER 43
3.3 GEOGRAPHIC SNAPSHOT OF APHERESIS MARKET 44
4 MARKET OVERVIEW 45
4.1 INTRODUCTION 45
4.2 MARKET DYNAMICS 45
4.2.1 DRIVERS 46
4.2.1.1 Rising prevalence of autoimmune and neurological disorders driving demand for therapeutic apheresis procedures 46
4.2.1.2 Rising demand for blood components and increasing emphasis on transfusion safety to support market expansion 46
4.2.1.3 Growing volume of complex oncological and transplant procedures to support growth of apheresis 47
4.2.1.4 Technological improvements in component-specific blood collection to support market expansion 48
4.2.1.5 Expanding adoption of cell and gene therapies to create growth opportunities for apheresis market 48
4.2.2 RESTRAINTS 49
4.2.2.1 High procedural and operational costs limit adoption of apheresis technologies 49
4.2.2.2 Limited adoption of apheresis donation procedures in emerging economies 50
4.2.2.3 Stringent donor eligibility criteria and limited donor availability to restrain apheresis procedures 50
4.2.2.4 Dearth of skilled professionals impacting adoption of apheresis procedures 51
4.2.3 OPPORTUNITIES 52
4.2.3.1 Adoption of apheresis procedures in leukemia and pediatric patients creating growth opportunities 52
4.2.3.2 Growing investments in emerging markets by governments and key industry players 52
4.2.4 CHALLENGES 53
4.2.4.1 Risk of procedure-related adverse events and donor safety concerns 53
4.2.4.2 Risk of transfusion-transmitted infections and inadequate blood screening infrastructure in emerging countries 54
4.3 UNMET NEEDS AND WHITE SPACES 54
4.3.1 UNMET NEEDS IN APHERESIS MARKET 54
4.3.2 WHITE SPACE OPPORTUNITIES 55
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 57
4.4.1 INTERCONNECTED MARKETS 57
4.4.2 CROSS-SECTOR OPPORTUNITIES 58
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 58
4.5.1 STRATEGIC MOVES IN APHERESIS MARKET 59
5 INDUSTRY TRENDS 60
5.1 PORTER’S FIVE FORCES ANALYSIS 60
5.1.1 THREAT FROM NEW ENTRANTS 61
5.1.2 THREAT FROM SUBSTITUTES 61
5.1.3 BARGAINING POWER OF SUPPLIERS 62
5.1.4 BARGAINING POWER OF BUYERS 62
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 63
5.2 MACROECONOMIC INDICATORS 63
5.2.1 INTRODUCTION 63
5.2.2 GDP TRENDS AND FORECAST 63
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 64
5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 65
5.3 SUPPLY CHAIN ANALYSIS 65
5.4 VALUE CHAIN ANALYSIS 66

5.5 ECOSYSTEM ANALYSIS 67
5.5.1 MANUFACTURERS 68
5.5.2 END USERS 69
5.5.3 REGULATORY BODIES 69
5.6 PRICING ANALYSIS 70
5.7 TRADE ANALYSIS 71
5.7.1 IMPORT DATA (HS CODE 901890) 71
5.7.2 EXPORT DATA FOR (HS CODE 901890) 71
5.8 REIMBURSEMENT SCENARIO 72
5.9 KEY CONFERENCES & EVENTS, 2026–2027 74
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 74
5.11 INVESTMENT & FUNDING SCENARIO 75
5.12 CASE STUDY ANALYSIS 76
5.13 IMPACT OF 2025 US TARIFF 77
5.13.1 INTRODUCTION 77
5.13.2 KEY TARIFF RATES 78
5.13.3 PRICE IMPACT ANALYSIS 78
5.13.4 IMPACT ON COUNTRY/REGION 79
5.13.5 IMPACT ON END-USE SEGMENTS 80
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 82
6.1 TECHNOLOGY ANALYSIS 82
6.1.1 KEY EMERGING TECHNOLOGIES 82
6.1.1.1 Automation and AI-enabled procedure optimization in apheresis systems 82
6.1.1.2 Closed-loop and automated cell therapy collection/manufacturing workflows 82
6.1.2 COMPLEMENTARY TECHNOLOGIES 83
6.1.2.1 Real-time biosensors and digital monitoring in apheresis procedures 83
6.1.2.2 RFID, barcode, and digital traceability technologies in blood and cell collection management 83
6.1.3 ADJACENT TECHNOLOGIES 84
6.1.3.1 Cell and gene therapy manufacturing technologies 84
6.1.3.2 Therapeutic filtration, adsorption, and extracorporeal blood purification technologies 84
6.2 TECHNOLOGY/PRODUCT ROADMAP 84
6.2.1 NEAR TERM (2025–2027) 85
6.2.2 MID-TERM (2028–2030) 85
6.2.3 LONG TERM (2030+) 85
6.3 PATENT ANALYSIS 86
6.3.1 JURISDICTION AND TOP APPLICANT ANALYSIS 86

6.4 FUTURE APPLICATIONS 88
6.4.1 AI-ENABLED AND DATA-DRIVEN APHERESIS PROCEDURE OPTIMIZATION 88
6.4.2 PERSONALIZED THERAPEUTIC APHERESIS 88
6.4.3 CONNECTED APHERESIS WORKFLOWS AND DIGITAL TRACEABILITY 89
6.5 IMPACT OF AI/GEN AI ON APHERESIS 89
6.5.1 INTRODUCTION 89
6.5.2 MARKET POTENTIAL OF AI IN APHERESIS 89
6.5.3 AI USE CASES 90
6.5.4 KEY COMPANIES IMPLEMENTING AI 91
7 SUSTAINABILITY & REGULATORY LANDSCAPE 93
7.1 REGULATORY LANDSCAPE 93
7.1.1 REGULATORY FRAMEWORK 93
7.1.1.1 North America 93
7.1.1.2 Europe 93
7.1.1.3 Asia Pacific 94
7.1.1.4 Latin America 94
7.1.1.5 Middle East & Africa 94
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
7.1.3 INDUSTRY STANDARDS 97
7.2 SUSTAINABILITY INITIATIVES 98
7.2.1 REDUCING SINGLE-USE APHERESIS WASTE 98
7.2.2 USE OF LOWER-IMPACT MATERIALS AND PACKAGING 98
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 98
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100
8.1 KEY STAKEHOLDERS & BUYING CRITERIA 100
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 100
8.1.2 BUYING CRITERIA 101
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 102
8.2.1 DECISION-MAKING PROCESS 102
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 102
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 103
8.2.4 MARKET PROFITABILITY 103
9 APHERESIS MARKET, BY TYPE 105
9.1 INTRODUCTION 106
9.2 DONOR APHERESIS 106
9.2.1 INCREASING BLOOD DONATIONS AND EXPANDING CELL THERAPY COLLECTIONS TO SUPPORT DONOR APHERESIS MARKET GROWTH 106

9.3 THERAPEUTIC APHERESIS 109
9.3.1 GROWING CLINICAL UTILIZATION OF THERAPEUTIC PLASMA EXCHANGE AND EXPANDING NEUROLOGICAL APPLICATIONS TO DRIVE MARKET 109
9.4 NEUROLOGICAL DISORDERS 111
9.4.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH 111
9.5 BLOOD DISORDERS 112
9.5.1 RISING PREVALENCE OF HEMATOLOGICAL AND GENETIC BLOOD DISORDERS TO DRIVE DEMAND 112
9.6 RENAL DISORDERS 114
9.6.1 RISING BURDEN OF CHRONIC KIDNEY DISEASE AND AUTOIMMUNE RENAL COMPLICATIONS TO DRIVE DEMAND 114
9.7 AUTOIMMUNE DISORDERS 116
9.7.1 INCREASING PREVALENCE OF AUTOIMMUNE DISORDERS AND CONTINUED CLINICAL IMPORTANCE OF THERAPEUTIC APHERESIS TO DRIVE GROWTH 116
9.8 METABOLIC DISORDERS 117
9.8.1 GROWING BURDEN OF DIABETES AND METABOLIC CONDITIONS TO SUPPORT THERAPEUTIC APHERESIS MARKET GROWTH 117
9.9 CARDIOVASCULAR DISORDERS 119
9.9.1 RISING LONG-TERM BURDEN OF CARDIOVASCULAR DISORDERS TO DRIVE MARKET GROWTH 119
9.10 OTHER DISORDERS 120
10 APHERESIS MARKET, BY END USER 122
10.1 INTRODUCTION 123
10.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS 123
10.2.1 INCREASING DEMAND FOR COMPONENT-SPECIFIC BLOOD COLLECTION AND COMMERCIAL PLASMA SUPPLY TO DRIVE MARKET GROWTH 123
10.3 HOSPITALS & TRANSFUSION CENTERS 125
10.3.1 EXPANDING TRANSFUSION REQUIREMENTS IN ONCOLOGY, TRANSPLANT, AND CRITICAL CARE SETTINGS TO DRIVE MARKET GROWTH 125
10.4 OTHER END USERS 126
11 APHERESIS MARKET, BY PROCEDURE 128
11.1 INTRODUCTION 129
11.2 PLASMAPHERESIS 129
11.2.1 INCREASING GLOBAL DEMAND FOR PLASMA-DERIVED THERAPIES AND THERAPEUTIC PLASMA EXCHANGE TO DRIVE MARKET GROWTH 129
11.3 PLATELETAPHERESIS 132
11.3.1 INCREASING DEMAND FOR PLATELET TRANSFUSIONS IN ONCOLOGY, TRANSPLANT, AND CRITICAL CARE SETTINGS TO DRIVE MARKET GROWTH 132
11.4 ERYTHROCYTAPHERESIS 134
11.4.1 INCREASING BURDEN OF SICKLE CELL DISEASE AND RISING DEMAND FOR TARGETED RED BLOOD CELL EXCHANGE PROCEDURES TO DRIVE GROWTH 134

11.5 LEUKAPHERESIS 136
11.5.1 EXPANDING CELL AND GENE THERAPY PIPELINE AND INCREASING CAR-T CELL MANUFACTURING ACTIVITIES TO DRIVE MARKET GROWTH 136
11.6 PHOTOPHERESIS 137
11.6.1 INCREASING TRANSPLANT PROCEDURES AND RISING USE OF IMMUNE-MODULATING THERAPIES TO SUPPORT MARKET GROWTH 137
11.7 OTHER PROCEDURES 139
12 APHERESIS MARKET, BY PRODUCT 141
12.1 INTRODUCTION 142
12.2 APHERESIS DEVICES 143
12.2.1 RISING DEMAND FOR PLASMA-DERIVED THERAPIES TO DRIVE SEGMENT GROWTH 143
12.3 APHERESIS DISPOSABLES 144
12.3.1 RECURRING UTILIZATION OF SINGLE-USE CONSUMABLES AND RISING THERAPEUTIC PROCEDURE VOLUMES TO DRIVE GROWTH 144
13 APHERESIS MARKET, BY TECHNOLOGY 147
13.1 INTRODUCTION 148
13.2 CENTRIFUGATION 148
13.3 CONTINUOUS FLOW CENTRIFUGATION 150
13.3.1 INCREASING NEED FOR HIGH-THROUGHPUT BLOOD COMPONENT COLLECTION AND EFFICIENT PLASMA PROCESSING TO DRIVE GROWTH 150
13.4 INTERMITTENT FLOW CENTRIFUGATION 152
13.4.1 INCREASING DEMAND FOR COST-EFFECTIVE AND FLEXIBLE APHERESIS SYSTEMS IN HEALTHCARE SETTINGS TO SUPPORT MARKET GROWTH 152
13.5 MEMBRANE SEPARATION 154
13.5.1 INCREASING UTILIZATION OF MEMBRANE-BASED PLASMA FILTRATION TECHNOLOGIES IN THERAPEUTIC APHERESIS TO DRIVE MARKET GROWTH 154
14 APHERESIS MARKET, BY REGION 156
14.1 INTRODUCTION 157
14.2 NORTH AMERICA 157
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 158
14.2.2 US 162
14.2.2.1 Strong economic capacity and high healthcare spending to support north america apheresis market growth 162
14.2.3 CANADA 164
14.2.3.1 Rising demand for blood components and plasma protein products to drive market growth 164
14.3 ASIA PACIFIC 167
14.3.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 167
14.3.2 CHINA 171
14.3.2.1 Expanding healthcare infrastructure and growing demand for advanced blood management procedures to accelerate growth 171
14.3.3 JAPAN 173
14.3.3.1 Aging-driven treatment demand and advanced hospital infrastructure to support market growth 173
14.3.4 INDIA 175
14.3.4.1 Large patient base and expanding healthcare infrastructure to drive market 175
14.3.5 AUSTRALIA 178
14.3.5.1 Strong healthcare infrastructure and growing demand for specialized therapies to support market growth 178
14.3.6 SOUTH KOREA 180
14.3.6.1 Advanced healthcare technologies and growing specialty care adoption to support market growth 180
14.3.7 THAILAND 182
14.3.7.1 Expanding specialty care infrastructure and rising chronic disease burden to support market growth 182
14.3.8 SINGAPORE 185
14.3.8.1 Advanced healthcare infrastructure and regional medical hub status to support market growth 185
14.3.9 REST OF ASIA PACIFIC 187
14.4 EUROPE 189
14.4.1 MACROECONOMIC OUTLOOK FOR EUROPE 189
14.4.2 GERMANY 192
14.4.2.1 High healthcare spending and strong reimbursement support to drive market growth 192
14.4.3 FRANCE 194
14.4.3.1 Centralized healthcare system and growing therapeutic apheresis utilization to propel growth 194
14.4.4 ITALY 196
14.4.4.1 Rising elderly population and growing demand for therapeutic procedures to drive growth 196
14.4.5 UK 198
14.4.5.1 Expanding apheresis infrastructure and specialized care services to support market growth 198
14.4.6 SPAIN 200
14.4.6.1 Growing chronic disease burden and expanding specialty treatment centers to support market growth 200
14.4.7 SWITZERLAND 202
14.4.7.1 Advanced healthcare funding and specialized treatment capabilities to support growth 202
14.4.8 NETHERLANDS 204
14.4.8.1 Advanced healthcare infrastructure and strong academic network to support market 204
14.4.9 REST OF EUROPE 206

14.5 LATIN AMERICA 208
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 208
14.5.2 BRAZIL 211
14.5.2.1 Cancer burden, blood donation recovery, and CAR-T access to strengthen market growth 211
14.5.3 MEXICO 213
14.5.3.1 Expanding leukemia treatment access and rising blood component demand to support market growth 213
14.5.4 REST OF LATIN AMERICA 216
14.6 MIDDLE EAST & AFRICA 218
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 218
14.6.2 GCC COUNTRIES 221
14.6.2.1 Expanding advanced healthcare infrastructure and cell therapy capabilities to support market 221
14.6.3 KINGDOM OF SAUDI ARABIA (KSA) 223
14.6.3.1 Expanding cell therapy infrastructure and clinical trial ecosystem to support market growth 223
14.6.3.2 United Arab Emirates (UAE) 225
14.6.3.2.1 Growing precision medicine initiatives and advanced oncology capabilities to support market growth 225
14.6.4 OTHER GCC COUNTRIES 227
14.6.5 REST OF MIDDLE EAST & AFRICA 229
15 COMPETITIVE LANDSCAPE 232
15.1 INTRODUCTION 232
15.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023–2026 232
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN APHERESIS MARKET 232
15.3 REVENUE ANALYSIS, 2023–2025 233
15.4 GLOBAL MARKET SHARE ANALYSIS, 2025 234
15.4.1 US: MARKET SHARE ANALYSIS, 2025 236
15.4.2 EUROPE: MARKET SHARE ANALYSIS, 2025 236
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 237
15.5.1 STARS 238
15.5.2 EMERGING LEADERS 238
15.5.3 PERVASIVE PLAYERS 238
15.5.4 PARTICIPANTS 238
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 240
15.5.5.1 Company footprint 240
15.5.5.2 Region footprint 240
15.5.5.3 Product footprint 241
15.5.5.4 Type footprint 241
15.5.5.5 Technology footprint 242

15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 243
15.6.1 PROGRESSIVE COMPANIES 243
15.6.2 RESPONSIVE COMPANIES 243
15.6.3 DYNAMIC COMPANIES 243
15.6.4 STARTING BLOCKS 243
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 244
15.7 COMPANY VALUATION AND FINANCIAL METRICS 246
15.7.1 FINANCIAL METRICS 246
15.7.2 COMPANY VALUATION 246
15.8 BRAND/PRODUCT COMPARISON 247
15.9 COMPETITIVE SCENARIO 247
15.9.1 PRODUCT LAUNCHES & APPROVALS 247
15.9.2 DEALS 248
15.9.3 EXPANSIONS 250
16 COMPANY PROFILES 251
16.1 KEY PLAYERS (APHERESIS PRODUCTS MARKET) 251
16.1.1 TERUMO CORPORATION 251
16.1.1.1 Business overview 251
16.1.1.2 Products offered 252
16.1.1.3 Recent developments 254
16.1.1.3.1 Product launches & approvals 254
16.1.1.3.2 Deals 254
16.1.1.3.3 Expansions 255
16.1.1.4 MnM view 255
16.1.1.4.1 Right to win 255
16.1.1.4.2 Strategic choices 256
16.1.1.4.3 Weaknesses & competitive threats 256
16.1.2 FRESENIUS SE & CO. KGAA 257
16.1.2.1 Business overview 257
16.1.2.2 Products offered 258
16.1.2.3 Recent developments 260
16.1.2.3.1 Product launches 260
16.1.2.3.2 Other developments 261
16.1.2.4 MnM view 261
16.1.2.4.1 Key strengths 261
16.1.2.4.2 Strategic choices 261
16.1.2.4.3 Weaknesses and competitive threats 261

16.1.3 FRESENIUS MEDICAL CARE AG 262
16.1.3.1 Business overview 262
16.1.3.2 Products offered 263
16.1.3.3 Recent developments 264
16.1.3.4 MnM view 264
16.1.3.4.1 Key strengths/Right to win 264
16.1.3.4.2 Strategic choices 264
16.1.3.4.3 Weaknesses and competitive threats 265
16.1.4 HAEMONETICS CORPORATION 266
16.1.4.1 Business overview 266
16.1.4.2 Products offered 267
16.1.4.3 Recent developments 268
16.1.4.3.1 Product launches 268
16.1.4.4 MnM view 268
16.1.4.4.1 Key strengths/Right to win 268
16.1.4.4.2 Strategic choices 269
16.1.4.4.3 Weaknesses and competitive threats 269
16.1.5 B. BRAUN SE 270
16.1.5.1 Business overview 270
16.1.5.2 Products offered 271
16.1.5.3 MnM view 273
16.1.5.3.1 Key strengths/Right to win 273
16.1.5.3.2 Strategic choices 273
16.1.5.3.3 Weaknesses and competitive threats 273
16.1.6 BD 274
16.1.6.1 Business overview 274
16.1.6.2 Products offered 274
16.1.6.3 Recent developments 276
16.1.6.3.1 Deals 276
16.1.6.3.2 Expansions 276
16.1.7 ASAHI KASEI MEDICAL CO., LTD. 277
16.1.7.1 Business overview 277
16.1.7.2 Products offered 277
16.1.7.3 Recent developments 278
16.1.7.3.1 Other developments 278
16.1.8 OTSUKA HOLDINGS CO., LTD. 279
16.1.8.1 Business overview 279
16.1.8.2 Products offered 280
16.1.9 MEDICA S.P.A 281
16.1.9.1 Business overview 281
16.1.9.2 Products offered 281

16.1.10 SUMITOMO BAKELITE CO., LTD. 282
16.1.10.1 Business overview 282
16.1.10.2 Products offered 283
16.1.10.3 MnM view 284
16.1.10.3.1 Right to win 284
16.1.10.3.2 Strategic choices 284
16.1.10.3.3 Weaknesses & competitive threats 284
16.1.11 KANEKA CORPORATION 285
16.1.11.1 Business overview 285
16.1.11.2 Products offered 286
16.1.11.3 Recent developments 288
16.1.11.3.1 Deals 288
16.1.11.3.2 Expansions 288
16.1.12 VANTIVE 289
16.1.12.1 Business overview 289
16.1.12.2 Products offered 289
16.1.12.3 Recent developments 290
16.1.12.3.1 Deals 290
16.1.12.3.2 Other developments 291
16.1.13 MILTENYI BIOTEC 292
16.1.13.1 Business overview 292
16.1.13.2 Products offered 292
16.1.13.3 Recent developments 293
16.1.13.3.1 Deals 293
16.1.13.3.2 Expansions 294
16.1.14 NIKKISO CO., LTD. 295
16.1.14.1 Business overview 295
16.1.14.2 Products offered 296
16.1.14.3 Recent developments 297
16.1.14.3.1 Deals 297
16.1.14.3.2 Other developments 297
16.1.15 TORAY INDUSTRIES, INC. 298
16.1.15.1 Business overview 298
16.1.15.2 Products offered 299
16.2 OTHER PLAYERS 300
16.2.1 MACOPHARMA SA 300
16.2.2 INFOMED SA 301
16.2.3 THERAKOS LLC. 301
16.2.4 MEDICAP GMBH 302
16.2.5 HAIER BIOMEDICAL 302
16.2.6 SICHUAN NIGALE BIOTECHNOLOGY CO, LTD. 303
16.2.7 JAFRON BIOMEDICAL CO., LTD. 304
16.2.8 SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD 305
16.2.9 KENTEC MEDICAL 306
16.2.10 SCINOMED LTD. 306
17 RESEARCH METHODOLOGY 307
17.1 RESEARCH DATA 307
17.1.1 SECONDARY DATA 308
17.1.1.1 Key data from secondary sources 309
17.1.2 PRIMARY DATA 310
17.1.2.1 Key industry insights 311
17.2 MARKET SIZE ESTIMATION METHODOLOGY 313
17.3 MARKET GROWTH RATE PROJECTIONS 316
17.4 DATA TRIANGULATION 318
17.5 RESEARCH ASSUMPTIONS 318
17.5.1 GROWTH RATE ASSUMPTIONS 319
17.6 RISK ASSESSMENT 319
17.7 LIMITATIONS 319
17.7.1 METHODOLOGY-RELATED LIMITATIONS 319
17.7.2 SCOPE-RELATED LIMITATIONS 319
17.8 RESEARCH LIMITATIONS 320
17.9 RISK ANALYSIS 320
18 APPENDIX 321
18.1 DISCUSSION GUIDE 321
18.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 326
18.3 CUSTOMIZATION OPTIONS 328
18.3.1 COMPANY INFORMATION 328
18.3.2 COUNTRY ANALYSIS 328
18.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 328
18.3.4 COUNTRY-LEVEL VOLUME ANALYSIS 328
18.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 328
18.4 RELATED REPORTS 328
18.5 AUTHOR DETAILS 329

LIST OF TABLES

TABLE 1 CURRENCY CONVERSION RATES, 2023–2026 35
TABLE 2 INDICATIVE BLOOD AND BLOOD COMPONENT UTILIZATION ACROSS MAJOR SURGICAL AND CLINICAL CONDITIONS 47
TABLE 3 ESTIMATED BLOOD DONATIONS, BY REGION, 2024–2025 50
TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS 51
TABLE 5 RECENT INVESTMENTS AND STRATEGIC ACTIVITIES IN CELL & GENE THERAPY ECOSYSTEM 53
TABLE 6 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 60
TABLE 7 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 63
TABLE 8 LIST OF KEY APHERESIS MANUFACTURERS 68
TABLE 9 LIST OF KEY END USERS 69
TABLE 10 LIST OF KEY REGULATORY BODIES 69
TABLE 11 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT,
2023–2025 (USD) 70
TABLE 12 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD) 70
TABLE 13 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 71
TABLE 14 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND) 71
TABLE 15 KEY US BILLING CODES USED FOR APHERESIS PROCEDURES 72
TABLE 16 US AVERAGE MEDICARE OUTPATIENT PAYMENT 73
TABLE 17 APHERESIS MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027 74
TABLE 18 FRESENIUS SE & CO. KGAA AMICUS APHERESIS DEVICE — THERAPEUTIC APHERESIS IN MYASTHENIA GRAVIS PATIENT 76
TABLE 19 TERUMO BCT’S SPECTRA OPTIA APHERESIS DEVICE — SWITCH FROM MANUAL TO AUTOMATED RED BLOOD CELL EXCHANGE IN BRAZIL 76
TABLE 20 TERUMO BCT + BOSTON CHILDREN’S HOSPITAL — OPTIMIZING STEM CELL COLLECTION IN SICKLE CELL DISEASE 77
TABLE 21 RECIPROCAL TARIFF RATES ADJUSTED BY US, 2024 78
TABLE 22 KEY PRODUCT-RELATED TARIFF 78
TABLE 23 NORTH AMERICA: IMPACT OF US TARIFF ON CANADA 79
TABLE 24 ASIA PACIFIC: IMPACT OF US TARIFF ON CHINA, JAPAN, AND INDIA 79
TABLE 25 EUROPE: IMPACT OF US TARIFF ON GERMANY AND UK 79
TABLE 26 LATIN AMERICA: IMPACT OF US TARIFF ON MEXICO 80
TABLE 27 APHERESIS MARKET: KEY PATENTS, 2023–2025 87
TABLE 28 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 29 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 30 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 31 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 32 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 33 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF APHERESIS 100
TABLE 34 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS, BY END USER 101
TABLE 35 APHERESIS MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES 102
TABLE 36 APHERESIS MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 103
TABLE 37 APHERESIS MARKET: KEY PROFITABILITY DRIVERS 104
TABLE 38 APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 106
TABLE 39 DONOR APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 108
TABLE 40 THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 110
TABLE 41 THERAPEUTIC APHERESIS MARKET, BY DISEASE TYPE, 2024–2031 (USD MILLION) 111
TABLE 42 NEUROLOGICAL DISORDERS: THERAPEUTIC APHERESIS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 112
TABLE 43 BLOOD DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 113
TABLE 44 RENAL DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 115
TABLE 45 AUTOIMMUNE DISORDERS: THERAPEUTIC APHERESIS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 117
TABLE 46 METABOLIC DISORDERS: THERAPEUTIC APHERESIS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 118
TABLE 47 CARDIOVASCULAR DISORDERS: THERAPEUTIC APHERESIS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 120
TABLE 48 OTHER DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 121
TABLE 49 APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 123
TABLE 50 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 124
TABLE 51 HOSPITALS & TRANSFUSION CENTERS APHERESIS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 126
TABLE 52 OTHER END USERS: APHERESIS MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 127
TABLE 53 APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 129
TABLE 54 PLASMAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 131
TABLE 55 PLATELETAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 133
TABLE 56 ERYTHROCYTAPHERESIS MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 135
TABLE 57 LEUKAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 137
TABLE 58 PHOTOPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 138
TABLE 59 OTHER PROCEDURES: APHERESIS MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 140
TABLE 60 APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 142
TABLE 61 APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS) 142
TABLE 62 COMMERCIAL APHERESIS DEVICES 143
TABLE 63 APHERESIS DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 144
TABLE 64 COMMERCIAL APHERESIS DISPOSABLES 145
TABLE 65 APHERESIS DISPOSABLES MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 146
TABLE 66 APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 148
TABLE 67 COMMERCIAL CENTRIFUGATION TECHNOLOGY DEVICES 148
TABLE 68 CENTRIFUGATION APHERESIS MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 149
TABLE 69 CONTINUOUS FLOW CENTRIFUGATION: APHERESIS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 151
TABLE 70 INTERMITTENT FLOW CENTRIFUGATION: APHERESIS MARKET,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 153
TABLE 71 SIZE OF BLOOD COMPONENTS 154
TABLE 72 COMMERCIAL MEMBRANE SEPARATION DEVICES 154
TABLE 73 MEMBRANE SEPARATION APHERESIS MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 155
TABLE 74 APHERESIS MARKET, BY REGION, 2024–2031 (USD MILLION) 157
TABLE 75 MAJOR APHERESIS MARKET PLAYERS IN NORTH AMERICA 158
TABLE 76 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 77 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 160
TABLE 78 NORTH AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 160
TABLE 79 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 160
TABLE 80 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 161
TABLE 81 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 161
TABLE 82 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT,
2024-2031 (THOUSAND UNITS) 161
TABLE 83 US: KEY MACROINDICATORS 162
TABLE 84 US: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 163
TABLE 85 US: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 163
TABLE 86 US: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 163
TABLE 87 US: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 164
TABLE 88 US: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 164
TABLE 89 CANADA: KEY MACROINDICATORS 165
TABLE 90 CANADA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 165
TABLE 91 CANADA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 165
TABLE 92 CANADA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 166
TABLE 93 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 166
TABLE 94 CANADA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 166
TABLE 95 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 96 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 169
TABLE 97 ASIA PACIFIC: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 169
TABLE 98 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 169
TABLE 99 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 170
TABLE 100 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 170
TABLE 101 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS) 170
TABLE 102 CHINA: KEY MACROINDICATORS 171
TABLE 103 CHINA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 171
TABLE 104 CHINA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 172
TABLE 105 CHINA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 172
TABLE 106 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 172
TABLE 107 CHINA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 173
TABLE 108 JAPAN: KEY MACROINDICATORS 173
TABLE 109 JAPAN: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 174
TABLE 110 JAPAN: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 174
TABLE 111 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 174
TABLE 112 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 175
TABLE 113 JAPAN: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 175
TABLE 114 INDIA: KEY MACROINDICATORS 176
TABLE 115 INDIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 176
TABLE 116 INDIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 176
TABLE 117 INDIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 177
TABLE 118 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 177
TABLE 119 INDIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 177
TABLE 120 AUSTRALIA: KEY MACROINDICATORS 178
TABLE 121 AUSTRALIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 178
TABLE 122 AUSTRALIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 179
TABLE 123 AUSTRALIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 179
TABLE 124 AUSTRALIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 179
TABLE 125 AUSTRALIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 180
TABLE 126 SOUTH KOREA: KEY MACROINDICATORS 180
TABLE 127 SOUTH KOREA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 181
TABLE 128 SOUTH KOREA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 129 SOUTH KOREA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 181
TABLE 130 SOUTH KOREA: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 182
TABLE 131 SOUTH KOREA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 182
TABLE 132 THAILAND: KEY MACROINDICATORS 183
TABLE 133 THAILAND: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 183
TABLE 134 THAILAND: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 183
TABLE 135 THAILAND: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 184
TABLE 136 THAILAND: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 184
TABLE 137 THAILAND: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 184
TABLE 138 SINGAPORE: KEY MACROINDICATORS 185
TABLE 139 SINGAPORE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 185
TABLE 140 SINGAPORE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 141 SINGAPORE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 186
TABLE 142 SINGAPORE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 186
TABLE 143 SINGAPORE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 187
TABLE 144 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 187
TABLE 145 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 188
TABLE 146 REST OF ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 188
TABLE 147 REST OF ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 188
TABLE 148 REST OF ASIA PACIFIC: APHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 189
TABLE 149 EUROPE: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 190
TABLE 150 EUROPE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 190
TABLE 151 EUROPE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 190
TABLE 152 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 191
TABLE 153 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 191
TABLE 154 EUROPE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 191
TABLE 155 EUROPE: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS) 192
TABLE 156 GERMANY: KEY MACROINDICATORS 192
TABLE 157 GERMANY: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 192
TABLE 158 GERMANY: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 193
TABLE 159 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 193
TABLE 160 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 193
TABLE 161 GERMANY: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 194
TABLE 162 FRANCE: KEY MACROINDICATORS 194
TABLE 163 FRANCE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 194
TABLE 164 FRANCE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 165 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 195
TABLE 166 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 195
TABLE 167 FRANCE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 196
TABLE 168 ITALY: KEY MACROINDICATORS 196
TABLE 169 ITALY: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 196
TABLE 170 ITALY: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 197
TABLE 171 ITALY: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 197
TABLE 172 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 197
TABLE 173 ITALY: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 198
TABLE 174 UK: KEY MACROINDICATORS 198
TABLE 175 UK: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 198
TABLE 176 UK: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 177 UK: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 199
TABLE 178 UK: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 199
TABLE 179 UK: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 200
TABLE 180 SPAIN: KEY MACROINDICATORS 200
TABLE 181 SPAIN: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 200
TABLE 182 SPAIN: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201
TABLE 183 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 201
TABLE 184 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 201
TABLE 185 SPAIN: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 202
TABLE 186 SWITZERLAND: KEY MACROINDICATORS 202
TABLE 187 SWITZERLAND: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 202
TABLE 188 SWITZERLAND: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 189 SWITZERLAND: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 203
TABLE 190 SWITZERLAND: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 203
TABLE 191 SWITZERLAND: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 204
TABLE 192 NETHERLANDS: KEY MACROINDICATORS 204
TABLE 193 NETHERLANDS: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 204
TABLE 194 NETHERLANDS: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 205
TABLE 195 NETHERLANDS: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 205
TABLE 196 NETHERLANDS: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 205
TABLE 197 NETHERLANDS: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 206
TABLE 198 REST OF EUROPE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 206
TABLE 199 REST OF EUROPE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 200 REST OF EUROPE: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 207
TABLE 201 REST OF EUROPE: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 207
TABLE 202 REST OF EUROPE: APHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 208
TABLE 203 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 204 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 209
TABLE 205 LATIN AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 209
TABLE 206 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 210
TABLE 207 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 210
TABLE 208 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 210
TABLE 209 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT,
2024-2031 (THOUSAND UNITS) 211
TABLE 210 BRAZIL: KEY MACROINDICATORS 211
TABLE 211 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 212
TABLE 212 BRAZIL: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 212
TABLE 213 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 212
TABLE 214 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 213
TABLE 215 BRAZIL: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 213
TABLE 216 MEXICO: KEY MACROINDICATORS 214
TABLE 217 MEXICO: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 214
TABLE 218 MEXICO: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 219 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 215
TABLE 220 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 215
TABLE 221 MEXICO: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 215
TABLE 222 REST OF LATIN AMERICA: APHERESIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 216
TABLE 223 REST OF LATIN AMERICA: APHERESIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 216
TABLE 224 REST OF LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 217
TABLE 225 REST OF LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 217
TABLE 226 REST OF LATIN AMERICA: APHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 217
TABLE 227 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 219
TABLE 228 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 219
TABLE 229 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 219
TABLE 230 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 220
TABLE 231 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 220
TABLE 232 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 220
TABLE 233 MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT,
2024-2031 (THOUSAND UNITS) 221
TABLE 234 GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 221
TABLE 235 GCC COUNTRIES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 236 GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 222
TABLE 237 GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 222
TABLE 238 GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION) 222
TABLE 239 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 223
TABLE 240 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 223
TABLE 241 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 224
TABLE 242 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 224
TABLE 243 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 224
TABLE 244 KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 225
TABLE 245 UNITED ARAB EMIRATES: KEY MACROINDICATORS 225
TABLE 246 UNITED ARAB EMIRATES: APHERESIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 226
TABLE 247 UNITED ARAB EMIRATES: APHERESIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 226
TABLE 248 UNITED ARAB EMIRATES: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 226
TABLE 249 UNITED ARAB EMIRATES: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 227
TABLE 250 UNITED ARAB EMIRATES: APHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 227
TABLE 251 OTHER GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 228
TABLE 252 OTHER GCC COUNTRIES: APHERESIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 228
TABLE 253 OTHER GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 228
TABLE 254 OTHER GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 229
TABLE 255 OTHER GCC COUNTRIES: APHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 229
TABLE 256 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 230
TABLE 257 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 230
TABLE 258 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE,
2024–2031 (USD MILLION) 230
TABLE 259 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 231
TABLE 260 REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER,
2024–2031 (USD MILLION) 231
TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY APHERESIS COMPANIES,
JANUARY 2023–MAY 2026 232
TABLE 262 APHERESIS MARKET: DEGREE OF COMPETITION 235
TABLE 263 APHERESIS MARKET: REGION FOOTPRINT 240
TABLE 264 APHERESIS MARKET: PRODUCT FOOTPRINT 241
TABLE 265 APHERESIS MARKET: TYPE FOOTPRINT 241
TABLE 266 APHERESIS MARKET: TECHNOLOGY FOOTPRINT 242
TABLE 267 APHERESIS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 244
TABLE 268 APHERESIS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 245
TABLE 269 APHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–MAY 2026 247
TABLE 270 APHERESIS MARKET: DEALS, JANUARY 2023–MAY 2026 248
TABLE 271 APHERESIS MARKET: EXPANSIONS, JANUARY 2023–MAY 2026 250
TABLE 272 TERUMO CORPORATION: COMPANY OVERVIEW 251
TABLE 273 TERUMO CORPORATION: PRODUCTS OFFERED 252
TABLE 274 TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–MAY 2026 254
TABLE 275 TERUMO CORPORATION: DEALS, JANUARY 2023–MAY 2026 254
TABLE 276 TERUMO CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026 255
TABLE 277 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW 257
TABLE 278 FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED 258
TABLE 279 FRESENIUS SE & CO. KGAA: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026 260
TABLE 280 FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2023–MAY 2026 260
TABLE 281 FRESENIUS SE & CO. KGAA: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 261
TABLE 282 FRESENIUS MEDICAL CARE AG: COMPANY OVERVIEW 262
TABLE 283 FRESENIUS MEDICAL CARE CORPORATION: PRODUCTS OFFERED 263
TABLE 284 FRESENIUS MEDICAL CARE AG: DEALS, JANUARY 2023–MAY 2026 264
TABLE 285 HAEMONETICS CORPORATION: COMPANY OVERVIEW 266
TABLE 286 HAEMONETICS CORPORATION: PRODUCTS OFFERED 267
TABLE 287 HAEMONETICS CORPORATION: PRODUCT LAUNCHES,
JANUARY 2023–MARCH 2026 268
TABLE 288 HAEMONETICS CORPORATION: DEALS, JANUARY 2023–MAY 2026 268
TABLE 289 B. BRAUN SE: COMPANY OVERVIEW 270
TABLE 290 BD: COMPANY OVERVIEW 274
TABLE 291 BD: PRODUCTS OFFERED 274
TABLE 292 BD: DEALS, JANUARY 2023–MAY 2026 276
TABLE 293 BD: EXPANSIONS, JANUARY 2023–MARCH 2026 276
TABLE 294 ASAHI KASEI MEDICAL CO., LTD.: COMPANY OVERVIEW 277
TABLE 295 ASAHI KASEI MEDICAL CO., LTD.: PRODUCTS OFFERED 277
TABLE 296 ASAHI KASEI MEDICAL CO., LTD.: OTHER DEVELOPMENTS,
JANUARY 2023–MAY 2026 278
TABLE 297 OTSUKA HOLDINGS CO., LTD.: COMPANY OVERVIEW 279
TABLE 298 OTSUKA HOLDINGS CO., LTD: PRODUCTS OFFERED 280
TABLE 299 MEDICA S.P.A: COMPANY OVERVIEW 281
TABLE 300 MEDICA S.P.A: PRODUCTS OFFERED 281
TABLE 301 SUMITOMO BAKELITE CO., LTD.: COMPANY OVERVIEW 282
TABLE 302 SUMITOMO BAKELITE CO., LTD.: PRODUCTS OFFERED 283
TABLE 303 KANEKA CORPORATION: COMPANY OVERVIEW 285
TABLE 304 KANEKA CORPORATION: PRODUCTS OFFERED 286
TABLE 305 KANEKA CORPORATION: DEALS, JANUARY 2023–MAY 2026 288
TABLE 306 KANEKA CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026 288
TABLE 307 VANTIVE: COMPANY OVERVIEW 289
TABLE 308 VANTIVE: PRODUCTS OFFERED 289
TABLE 309 VANTIVE: DEALS, JANUARY 2023–MAY 2026 290
TABLE 310 VANTIVE: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 291
TABLE 311 MILTENYI BIOTEC: COMPANY OVERVIEW 292
TABLE 312 MILTENYI BIOTEC: PRODUCTS OFFERED 292
TABLE 313 MILTENYI BIOTEC: DEALS, JANUARY 2023–MAY 2026 293
TABLE 314 MILTENYI BIOTEC: EXPANSIONS, JANUARY 2023–MARCH 2026 294
TABLE 315 NIKKISO CO., LTD.: COMPANY OVERVIEW 295
TABLE 316 NIKKISO CO., LTD.: PRODUCTS OFFERED 296
TABLE 317 NIKKISO CO., LTD: DEALS, JANUARY 2023–MAY 2026 297
TABLE 318 NIKKISO CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026 297
TABLE 319 TORAY INDUSTRIES, INC.: COMPANY OVERVIEW 298
TABLE 320 TORAY INDUSTRIES, INC.: PRODUCTS OFFERED 299
TABLE 321 MACOPHARMA SA: COMPANY OVERVIEW 300
TABLE 322 INFOMED SA: COMPANY OVERVIEW 301
TABLE 323 THERAKOS LLC.: COMPANY OVERVIEW 301
TABLE 324 MEDICAP GMBH: COMPANY OVERVIEW 302
TABLE 325 HAIER BIOMEDICAL: COMPANY OVERVIEW 302
TABLE 326 SICHUAN NIGALE BIOTECHNOLOGY CO, LTD.: COMPANY OVERVIEW 303
TABLE 327 JAFRON BIOMEDICAL CO., LTD.: COMPANY OVERVIEW 304
TABLE 328 SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD: COMPANY OVERVIEW 305
TABLE 329 KENTEC MEDICAL: COMPANY OVERVIEW 306
TABLE 330 SCINOMED LTD.: COMPANY OVERVIEW 306
TABLE 331 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON APHERESIS MARKET 317

LIST OF FIGURES

FIGURE 1 MARKET SCENARIO 38
FIGURE 2 GLOBAL APHERESIS MARKET, 2024–2031 38
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN APHERESIS MARKET,
2023–2026 39
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF APHERESIS MARKET 40
FIGURE 5 HIGH-GROWTH SEGMENTS, 2026–2031 40
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST GROWTH, IN TERMS OF VALUE, DURING FORECAST PERIOD 41
FIGURE 7 GROWING INCIDENCE OF CHRONIC DISEASES AND WIDER ADOPTION OF THERAPEUTIC APHERESIS TO DRIVE MARKET GROWTH 42
FIGURE 8 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2025 43
FIGURE 9 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 44
FIGURE 10 APHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45
FIGURE 11 APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 61
FIGURE 12 APHERESIS MARKET: SUPPLY CHAIN ANALYSIS 65
FIGURE 13 APHERESIS MARKET: VALUE CHAIN ANALYSIS 66
FIGURE 14 APHERESIS MARKET ECOSYSTEM 68
FIGURE 15 REVENUE SHIFT AND NEW REVENUE POCKETS FOR APHERESIS MARKET 75
FIGURE 16 INVESTMENT & FUNDING SCENARIO 76
FIGURE 17 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR APHERESIS PATENTS, JANUARY 2015–MAY 2026 86
FIGURE 18 APHERESIS MARKET: AI USE CASES 91
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF APHERESIS PRODUCTS 100
FIGURE 20 KEY BUYING CRITERIA FOR APHERESIS PRODUCTS, BY END USER 101
FIGURE 21 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES, 2025 158
FIGURE 22 NORTH AMERICA: APHERESIS MARKET SNAPSHOT 159
FIGURE 23 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT 168
FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS, 2023–2025 (USD MILLION) 234
FIGURE 25 GLOBAL MARKET SHARE ANALYSIS, 2025 235
FIGURE 26 US: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 236
FIGURE 27 EUROPE: MARKET SHARE ANALYSIS, 2025 236
FIGURE 28 APHERESIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 239
FIGURE 29 APHERESIS MARKET: COMPANY FOOTPRINT 240
FIGURE 30 APHERESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 244
FIGURE 31 EV/EBITDA OF KEY VENDORS 246
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 246
FIGURE 33 APHERESIS MARKET: BRAND/PRODUCT COMPARISON 247
FIGURE 34 TERUMO CORPORATION: COMPANY SNAPSHOT (2025) 252
FIGURE 35 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2025) 258
FIGURE 36 FRESENIUS MEDICAL CARE AG: COMPANY SNAPSHOT (2025) 263
FIGURE 37 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2025) 267
FIGURE 38 B. BRAUN SE: COMPANY SNAPSHOT (2025) 271
FIGURE 39 BD: COMPANY SNAPSHOT (2025) 275
FIGURE 40 OTSUKA HOLDINGS CO., LTD: COMPANY SNAPSHOT (2025) 280
FIGURE 41 SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2025) 283
FIGURE 42 KANEKA CORPORATION: COMPANY SNAPSHOT (2025) 286
FIGURE 43 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2025) 296
FIGURE 44 TORAY INDUSTRIES, INC.: COMPANY SNAPSHOT (2025) 299
FIGURE 45 RESEARCH DESIGN 307
FIGURE 46 PRIMARY SOURCES 310
FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE) 311
FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (DEMAND SIDE) 312
FIGURE 49 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 312
FIGURE 50 GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH) 313
FIGURE 51 APHERESIS MARKET SIZE ANALYSIS, 2025 313
FIGURE 52 MARKET SIZE ESTIMATION FOR APHERESIS: REVENUE SHARE ANALYSIS 314
FIGURE 53 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 315
FIGURE 54 APHERESIS MARKET: CAGR PROJECTIONS, 2026–2031 316
FIGURE 55 DATA TRIANGULATION METHODOLOGY 318

---

---